Merz North America Announces Approval of Naftin® (Naftifine HCl) Gel 2% for the Treatment of Interdigital-Type Tinea ... GREENSBORO, N.C.--(BUSINESS WIRE)--Merz North America (an affiliate of the global Merz Pharma Group) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Naftin® (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis. “Our passion for therapeutic innovation is one of the hallmarks of our business,” said Bill Humphries, president & CEO ...
July 1, 2013 - Business Wire